SCHEMBL13158407

SCHEMBL13158407

CCNC(=O)Nc1ccc(-n2nnc(C(=O)NC3CC3)c2C)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PTGS2 P35354 5/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.43
▸ ALOX12 P18054 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ ALPI P09923 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SMURF1 Q9HCE7 2/20 0.41
▸ RIPK1 Q13546 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13158410 0.88 TP53 (0.51) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL13158416 0.88 TP53 (0.45) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL3106601 0.88 ROCK1 (0.47) ALDH1A1MAPTKMT2ARIPK1EPHX2
SCHEMBL13158409 0.87 TP53 (0.52) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL13158414 0.87 TP53 (0.58) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL13158348 0.87 TP53 (0.50) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL3105762 0.86 PTGS2 (0.46) TP53ALDH1A1PTGS2CA1CA2
SCHEMBL13158415 0.85 KDM4E (0.48) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL13158352 0.85 TP53 (0.48) TP53KDM4EALDH1A1LMNAGAA
SCHEMBL13158422 0.84 TP53 (0.52) TP53KDM4EALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 TP53 2716/4885KDM4E 3414/4885ALDH1A1 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback